Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 7 | 2023 | 538 | 1.190 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2025 | 5 | 0.960 |
Why?
|
| Folic Acid | 1 | 2020 | 292 | 0.600 |
Why?
|
| Embryonic Stem Cells | 1 | 2018 | 170 | 0.550 |
Why?
|
| DEAD-box RNA Helicases | 3 | 2025 | 121 | 0.490 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 543 | 0.440 |
Why?
|
| Hemoglobinuria, Paroxysmal | 5 | 2024 | 20 | 0.410 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 3 | 2021 | 24 | 0.370 |
Why?
|
| Hematologic Neoplasms | 2 | 2025 | 286 | 0.350 |
Why?
|
| Mutation | 5 | 2024 | 5807 | 0.310 |
Why?
|
| Signal Transduction | 1 | 2020 | 4532 | 0.300 |
Why?
|
| Prognosis | 3 | 2025 | 4554 | 0.230 |
Why?
|
| Disease Susceptibility | 1 | 2025 | 297 | 0.210 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2023 | 162 | 0.210 |
Why?
|
| Germ-Line Mutation | 1 | 2025 | 333 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 1 | 2025 | 353 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 138 | 0.200 |
Why?
|
| Minors | 1 | 2021 | 4 | 0.200 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2021 | 64 | 0.190 |
Why?
|
| Refugees | 1 | 2021 | 30 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 548 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 226 | 0.180 |
Why?
|
| Disease Management | 1 | 2025 | 519 | 0.180 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2021 | 120 | 0.180 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 301 | 0.180 |
Why?
|
| Histones | 2 | 2021 | 534 | 0.180 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2021 | 355 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 3 | 2011 | 1015 | 0.160 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 65 | 0.160 |
Why?
|
| Bone Marrow | 1 | 2020 | 325 | 0.160 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 145 | 0.150 |
Why?
|
| Antioxidants | 1 | 2020 | 337 | 0.150 |
Why?
|
| Nuclear Proteins | 2 | 2021 | 1272 | 0.140 |
Why?
|
| Chromosome Aberrations | 1 | 2020 | 621 | 0.140 |
Why?
|
| Glutamine | 1 | 2018 | 210 | 0.130 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 3342 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2012 | 504 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 530 | 0.110 |
Why?
|
| Humans | 16 | 2025 | 124332 | 0.110 |
Why?
|
| Disease Progression | 1 | 2019 | 2038 | 0.100 |
Why?
|
| Hemosiderin | 1 | 2012 | 2 | 0.100 |
Why?
|
| Iron Overload | 1 | 2012 | 15 | 0.100 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 38 | 0.090 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2303 | 0.090 |
Why?
|
| Animals | 4 | 2025 | 34134 | 0.080 |
Why?
|
| Complement C3 | 1 | 2009 | 47 | 0.080 |
Why?
|
| Neoplasms | 1 | 2023 | 2795 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2009 | 207 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 2428 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 4422 | 0.070 |
Why?
|
| Bone Marrow Diseases | 1 | 2024 | 41 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2009 | 662 | 0.060 |
Why?
|
| Middle Aged | 5 | 2025 | 26442 | 0.050 |
Why?
|
| Forensic Sciences | 1 | 2021 | 2 | 0.050 |
Why?
|
| Principal Component Analysis | 1 | 2021 | 142 | 0.050 |
Why?
|
| Family | 1 | 2023 | 567 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2021 | 295 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2021 | 333 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 4353 | 0.040 |
Why?
|
| Mice | 3 | 2021 | 17722 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 354 | 0.040 |
Why?
|
| Software | 1 | 2023 | 685 | 0.040 |
Why?
|
| Male | 6 | 2025 | 60988 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2018 | 21 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 1598 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 290 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 95 | 0.040 |
Why?
|
| Female | 6 | 2025 | 66265 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 261 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 662 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2019 | 719 | 0.030 |
Why?
|
| Base Sequence | 1 | 2021 | 3093 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2018 | 623 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2019 | 578 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 1701 | 0.030 |
Why?
|
| Young Adult | 2 | 2025 | 8978 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2020 | 778 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2018 | 261 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2824 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 3050 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 3133 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2020 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2025 | 6467 | 0.030 |
Why?
|
| Adult | 3 | 2025 | 29378 | 0.020 |
Why?
|
| Adolescent | 2 | 2025 | 19353 | 0.020 |
Why?
|
| Complement Membrane Attack Complex | 1 | 2011 | 7 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1674 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 1659 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2011 | 298 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 4730 | 0.020 |
Why?
|
| Graft Survival | 1 | 2011 | 528 | 0.020 |
Why?
|
| Splenectomy | 1 | 2008 | 64 | 0.020 |
Why?
|
| Aged | 1 | 2025 | 19460 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2025 | 16223 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2008 | 306 | 0.020 |
Why?
|
| Cell Survival | 1 | 2009 | 806 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 802 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1127 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 3576 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 12279 | 0.010 |
Why?
|